News & blog

Blueberry Therapeutics raises £3m

An Alderley Park-based drug company has raised £3m to help it progress into human clinical trials thanks to an investment by the Greater Manchester and Cheshire Life Sciences Fund.

The investment in Blueberry Therapeutics was led by the Catapult Ventures-managed fund and included participation from San Francisco-based InClin Investments as well as a number of private investors.

The funding will support the progress of its treatment for onychomycosis (fungal nail infection) and associated tinea pedis (athlete’s foot) into clinical development

Dr John Ridden, chief executive and co-founder of Blueberry Therapeutics, said: “We’re delighted to have secured this funding, which will enable us to move our lead program to treat onychomycosis with associated tinea pedis into human clinical trials with the ambition of moving into phase III trials early in 2017. Read More